Akthelia Pharmaceuticals will attend the Nordic Life Science Days Summit in Copenhagen, 9 - 30 November 2023
REYKJAVIK, Iceland -- 30 October, 2023 -- Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, will attend the 2023 Nordic Life Science Days Summit in Copenhagen.
To arrange a meeting with CEO Egill Masson, please contact us.
ABOUT AKTHELIA PHARMACEUTICALS
Akthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.
Akthelia’s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.
Egill Masson CEO firstname.lastname@example.org
Akthelia Pharmaceuticals Grandagarði 16 101 Reykjavik Iceland